On 11/19/10, Pfizer and Bristol Myers Squibb discontinued the APPRAISE-2 phase 3 trial of Apixiban in high risk patients with acute coronary syndrome. Apixiban bleeding risks were not offset by its antithrombotic benefit in the high-risk patient population. Details are available from theheart.org. At least two trials appear to show that Apixiban, which is a direct anti-Xa oral antithrombotic, is effective at stroke prevention in atrial fibrillation. The oral direct anti-thrombin drug Dabigatran (Pradaxa, Boehringer-Ingelheim) was released by the US FDA for stroke prevention in October.